Important Information for Sage Therapeutics Investors
As an investor in Sage Therapeutics, Inc., it is crucial to stay informed about ongoing legal proceedings that may impact your investment. Recently, the Rosen Law Firm has issued reminders for individuals who purchased Sage securities that they may be entitled to compensation under current class action claims. This is particularly pertinent for those who acquired shares during the specified class period, from April 12, 2021, to July 23, 2024.
Understanding the Class Action
The lead plaintiff deadline is set for October 28, 2024. If you have experienced losses exceeding $100,000, it’s crucial to consider your legal options. Participation in this class action might allow you to recover some of your financial losses without upfront costs, as the Rosen Law Firm operates on a contingency fee basis.
What Investors Should Know
By joining the class action, you won't incur costs at the outset, but rather, the law firm will cover the expenses necessary to process your claim. If you end up winning, their fees will be taken from the recovery amount. This system is designed to ensure that all investors can seek justice without financial barriers.
The Case Against Sage Therapeutics
The allegations made in the lawsuit revolve around misleading statements made by Sage Therapeutics regarding their product efficacy. Key claims include:
Specific Allegations
1. The drug zuranolone was promoted as being effective in treating major depressive disorder (MDD), yet evidence suggested it was less effective than presented.
2. The likelihood of the U.S. Food and Drug Administration (FDA) approving the zuranolone application in its current form was low, undermining previous assertions made by the company.
3. Sage-718's efficacy for mild cognitive impairment was claimed to be overstated, leading to investor misrepresentations.
These misleading statements caused significant losses to investors, who rightfully expect transparency in the firms they trust.
Choosing the Right Legal Representation
When selecting a law firm to represent your case, it’s vital to choose one with a strong track record in securities class actions. Many firms simply pass clients onto other attorneys that do the litigation. Rosen Law Firm has proven its effectiveness and success in this arena, making them a reputable choice for affected investors.
Track Record of Rosen Law Firm
Rosen Law Firm has secured landmark settlements and is highly recognized for their commitment to investor rights. In recent years, they have recovered substantial sums for victims of misleading corporate conduct. This established history suggests that they can offer the experienced legal support necessary for navigating complex securities class actions.
Steps to Take Now
If you believe you qualify for participation in the Sage Therapeutics class action, you should act swiftly. It's advisable to reach out to Rosen Law Firm to discuss your situation. They can provide tailored guidance and help you understand your options under the current claims. You can also retain your choice of counsel, underscoring the importance of making informed decisions about who represents your interests in legal matters.
Frequently Asked Questions
What is the deadline to join the Sage Therapeutics class action?
The deadline to join the class action lawsuit is October 28, 2024.
How can I participate in the class action?
To join, contact the Rosen Law Firm directly through their website or phone number.
Are there any costs involved in joining the class action?
Joining the class action should not incur any upfront costs as the Rosen Law Firm operates on a contingency basis.
What claims are being made against Sage Therapeutics?
Allegations include that Sage Therapeutics misrepresented the effectiveness of their products and failed to disclose essential information impacting investors.
Who can I contact for more information?
You can reach out to Phillip Kim, Esq. at the Rosen Law Firm for detailed inquiries regarding your participation in the class action.
